Jonathan Schwartz
Technik-/Wissenschafts-/F&E-Leiter bei ROCKET PHARMACEUTICALS, INC.
Vermögen: 4 Mio $ am 30.04.2024
Aktive Positionen von Jonathan Schwartz
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 26.03.2024 | - |
Corporate Officer/Principal | 04.04.2023 | 26.03.2024 |
Karriereverlauf von Jonathan Schwartz
Ehemalige bekannte Positionen von Jonathan Schwartz
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2014 | 01.01.2016 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Corporate Officer/Principal | - | - |
Ausbildung von Jonathan Schwartz
Brown University | Undergraduate Degree |
Washington University in St. Louis | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ROCKET PHARMACEUTICALS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 3 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Health Services |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Jonathan Schwartz
- Erfahrung